Combined THC and CBD to treat pain in epidermolysis bullosa: a report of three cases

Nicholas Schrader*, JC DUIPMANS, Bouwe Molenbuur, André Wolff, Marcel F. Jonkman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
311 Downloads (Pure)

Abstract

Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by intense pain related to disease pathology and care-based interventions. Opioid-based therapies underpin pain-care in EB however are unable to provide adequate analgesia in a significant proportion of patients. Cannabinoid-based medicines (CBMs) have been increasingly studied for pain conditions of various etiologies and pose as a novel dimension for pain-care in EB. We present three cases of EB who were prescribed pharmaceutical-grade sublingually administered CBMs comprising tetrahydrocannabinol (THC) and cannabidiol (CBD). All three patients reported improved pain scores, reduced pruritus and reduction in overall analgesic drug intake. This article is protected by copyright. All rights reserved
Original languageEnglish
Pages (from-to)922-924
Number of pages3
JournalBRITISH JOURNAL OF DERMATOLOGY
Volume180
Issue number4
DOIs
Publication statusPublished - Apr-2019

Cite this